Browse medicines
Some records contain detailed evidence; others currently contain only basic identity and regulatory information. Reviewed conclusions appear only when they are available for a specific use and group of people.
Showing 1–51 of 51 records
Semaglutide (Ozempic / Wegovy / Rybelsus)
Peptide medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Type 2 diabetes, obesity, and heart and kidney risk that comes with them
Desmopressin (DDAVP / Stimate / Nocdurna / Noctiva)
Peptide medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Passing far too much urine because the body is missing the hormone that concentrates it — and, separately, bleeding in mild haemophilia A or mild von Willebrand disease
Liraglutide (Victoza / Saxenda)
Peptide medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Type 2 diabetes and long-term weight management
Dulaglutide (Trulicity)
Peptide medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Type 2 diabetes, including in people who have not yet had a heart attack
Exenatide (Byetta / Bydureon / Bydureon BCise)
Peptide medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Type 2 diabetes
Teriparatide (Forteo / Bonsity)
Peptide medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Severe bone thinning, where the aim is to build new bone rather than only slow its loss
Tirzepatide (Mounjaro / Zepbound)
Peptide medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Type 2 diabetes, obesity, and obesity-related sleep apnoea
Octreotide (Octreotide Acetate (Preservative Free) / Sandostatin / Octreotide Acetate Preservative Free / Mycapssa / Sandostatin Lar / Bynfezia)
Peptide medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Profuse watery diarrhea associated with VIP-secreting tumors
Abaloparatide (Tymlos)
Peptide medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Postmenopausal women with osteoporosis at high risk for fracture (defined as a history of osteoporotic fracture or multiple risk factors
Defibrotide (Defitelio)
Peptide medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
DEFITELIO is indicated for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT). DEFITELIO is indicated for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT). ( 1 )
Ecallantide (Kalbitor)
Peptide medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Treatment of acute attacks of hereditary angioedema
Elamipretide (Forzinity)
Peptide medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Muscle strength
Eptifibatide (Integrilin)
Peptide medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Eptifibatide injection is a platelet aggregation inhibitor indicated for: • Treatment of acute coronary syndrome (ACS) managed medically or with percutaneous coronary intervention (PCI) ( 1.1 ) • Treatment of patients undergoing PCI (including intracoronary stenting) ( 1.2 ) 1.1 Acute Coronary Syndrome (ACS) Eptifibatide injection is indicated to decrease the rate of a combined endpoint of death or new myocardial infarction (MI) in patients with ACS (unstable angina [UA]/non-ST- elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those undergoing…
Albiglutide (Tanzeum)
Peptide medicineApproved in the United States (FDA)Expanded recordGoserelin (Zoladex)
Peptide medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Locally confined carcinoma of the prostate ( 1
Lixisenatide (Adlyxin)
Peptide medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Diabetic ketoacidosis
Ziconotide (Prialt)
Peptide medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Severe chronic pain
Lanreotide (Somatuline Depot)
Peptide medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tu
Oxytocin (Pitocin / Syntocinon / Oxytocin 10 USP Units in Dextrose 5% / Oxytocin 5 USP Units in Dextrose 5% / Oxytocin 20 USP Units in Dextrose 5%)
Peptide medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
The medical rather than the elective induction of labor
Vasopressin (Vasostrict / Vasopressin in Sodium Chloride 0.9% / Vasopressin in 0.9% Sodium Chloride / Vasopressin in Dextrose 5% / Pitressin Tannate)
Peptide medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Blood pressure
Tesamorelin (Egrifta)
Peptide medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Excess abdominal fat in HIV-infected adult patients with lipodystrophy
Etelcalcetide (Parsabiv)
Peptide medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Secondary hyperparathyroidism
Lypressin (Diapid)
Peptide medicineApproved in the United States (FDA)Expanded recordPramlintide (Symlin / Symlinpen)
Peptide medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Type 1 or type 2 diabetes who use mealtime insulin and have failed to achieve desired glycemic control despite optimal insulin therapy
Gallium Ga-68 Gozetotide (Gallium Ga-68 Psma-11 / Gozellix / Locametz / Illuccix)
Peptide medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions
Bremelanotide (Vyleesi (Autoinjector) / Vyleesi)
Peptide medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
VYLEESI is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to: A co-existing medical or psychiatric condition, Problems with the relationship, or The effects of a medication or drug substance. Acquired HSDD refers to HSDD that develops in a patient who previously had no problems with sexual desire. Generalized HSDD refers to HSDD that occurs regardless of the type of stimulation, situation or partner.
Enfuvirtide (Fuzeon)
Peptide medicineApproved in the United States (FDA)Expanded recordMacimorelin (Macrilen)
Peptide medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
The diagnosis of adult growth hormone deficiency
Motixafortide (Aphexda)
Peptide medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
APHEXDA is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. APHEXDA, a hematopoietic stem cell mobilizer, is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. ( 1 )
Nafarelin (Synarel)
Peptide medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Treatment of central precocious puberty
Nesiritide (Natrecor)
Peptide medicineApproved in the United States (FDA)Expanded recordNovobiocin (Albamycin)
Peptide medicineApproved in the United States (FDA)Expanded recordPalopegteriparatide (Yorvipath)
Peptide medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Hypoparathyroidism
Peginesatide (Omontys Preservative Free / Omontys)
Peptide medicineApproved in the United States (FDA)Expanded recordAfamelanotide (Scenesse)
Peptide medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Pain free light exposure
Capromab Pendetide (Prostascint)
Peptide medicineApproved in the United States (FDA)Expanded recordGonadorelin (Factrel / Lutrepulse Kit)
Peptide medicineApproved in the United States (FDA)Expanded recordHistrelin (Supprelin / Vantas)
Peptide medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Central precocious puberty
Linaclotide (Linzess)
Peptide medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
LINZESS is indicated for the treatment of: • irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients 7 years of age and older • chronic idiopathic constipation (CIC) in adults • functional constipation (FC) in pediatric patients 2 years of age and older LINZESS is a guanylate cyclase-C agonist indicated for treatment of: Irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients 7 years of age and older. ( 1 ) Chronic idiopathic constipation (CIC) in adults. ( 1 ) Functional constipation (FC) in pediatric patients 2 years of age and older.
Navepegritide (Yuviwel)
Peptide medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Linear growth
Protirelin (Thypinone / Thyrel Trh)
Peptide medicineApproved in the United States (FDA)Expanded recordSetmelanotide (Imcivree)
Peptide medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Excess body weight and maintain weight reduction long term
Terlipressin (Terlivaz)
Peptide medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Kidney function
Plecanatide (Trulance / Trulance Immediate Release)
Peptide medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
TRULANCE is indicated in adults for the treatment of: chronic idiopathic constipation (CIC). irritable bowel syndrome with constipation (IBS-C). TRULANCE is a guanylate cyclase-C agonist indicated in adults for treatment of: chronic idiopathic constipation (CIC). ( 1 ) irritable bowel syndrome with constipation (IBS-C). ( 1 )
Streptozocin (Zanosar)
Peptide medicineApproved in the United States (FDA)Expanded recordTechnetium Tc-99m Apcitide (Acutect)
Peptide medicineApproved in the United States (FDA)Expanded recordTeduglutide (Gattex Kit / Gattex)
Peptide medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Adults and pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support
Technetium Tc-99m Depreotide (Neo Tect Kit)
Peptide medicineApproved in the United States (FDA)Expanded recordTriptorelin (Trelstar / Triptodur Kit)
Peptide medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Pediatric patients 2 years of age and older with central precocious puberty
Trofinetide (Daybue Stix / Daybue)
Peptide medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Rett syndrome
Vosoritide (Voxzogo)
Peptide medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Linear growth